Pamaquine, synthesized in 1926, was introduced in the treatment of malaria as a schizonticide. It was soon found, however, that the great schizonticidal activity which it possessed in cathemerium malaria of canaries did not obtain in the human malarias. It was shown to be relatively ineffective in acute attacks of vivax malaria and to have only minimal activity against the asexual forms of P. falciparum, although it did eradicate the gametocytes in this infection. In addition, the general usefulness of pamaquine was limited by the frequent occurrence of toxic effects with doses in the therapeutic range. Nonetheless, evidence was advanced favoring both a prophylactic (1, 2, 3) and curative action (4) in vivax malaria. The toxicity of the drug and an incomplete understanding of the biology of vivax malaria led the commission on malaria of the Health Organization of the League of Nations (5) to state that its prophylactic action was not practical and to discount the work of Sinton on its curative action (4) . The commission recommended that pama- * Partial effect on parasites. 6 All dosages are recorded in terms of the free base. plete temporary suppression of both parasites and fever in every instance. Daily doses of 4-20 mg. produced partial or temporary suppression of parasitemia, except in one individual whose infection was not definitely affected by a daily dose of 4 mg. In no instance was a Class III (permanent) effect observed. The effect obtained was not as clearly related to plasma drug concentration as to the daily dose of drug. The period of therapy was extended to eight days in four additional patients (Table II) . Complete and permanent (Class III) interruption of the infection was produced in one subject who received a daily dose of 90 mg.
Blood-induced falciparum malaria. Observations on the suppressive activity of pamaquine in blood-induced falciparum (McClendon) malaria were obtained in eight individuals (Table III) . The effect of 30 mg. daily for the six-day test pe- A summary of the results of these experiments is given in Table V . It may be concluded from these data that a combination of pamaquine and quinine has a curative action in Chesson vivax malaria, providing the drugs are administered concurrently in high dosage and for a long period of time. The groups are too small and the variables too many, to warrant further analysis of the data..
Other studies were conducted by the University of Chicago group at Stateville (11) and by ourselves at the U. S. Disciplinary Barracks, Green Haven, in order to determine more accurately the quantitative nature of this curative action.
The patients in the Green Haven studies were divided into two groups. Twelve volunteers were treated in their primary attacks as well as in each subsequent relapse, with 2 grams of quinine daily for 16 days. The primary attacks in 18 subjects were treated with quinine, 2 grams daily for 16 days, plus pamaquine, 60 mg. daily for 14 days, beginning on the third day of quinine therapy. Each subsequent attack in these individuals was treated with the same regimen. This dosage of Table V ). It is believed that the difference is attributable largely to the heavier sporozoite inoculum used in the Green Haven studies.
The results of treatment with simultaneous pamaquine (60 mg. daily) and quinine differ sharply from those obtained with quinine alone. Although 13 of the 18 subjects had at least one relapse, the interval from treatment to first relapse was markedly prolonged and variable. The incidence of second relapse was markedly reduced and only one-third relapse was observed. Within any group of similarly treated patients there was no relationship between, plasma drug concentration and the occurrence of relapse.
DISCUSSION
The suppressive action of pamaquine is more marked in vivax than in falciparum malaria but there exists at least as much difference between different strains of falciparum as between vivax and falciparum. However, it is evident that, in doses which approach the maximum tolerated, pamaquine is a relatively ineffective suppressive drug against both vivax and falciparum malaria, being, in general, incapable of effecting a complete interruption of the schizogonous cycle. For this reason, in studies designed to test the curative action of pamaquine, the erythrocytic phase of vivax malaria must be eradicated with a more potent suppressive agent. This is necessary to insure that each recurrence of activity represents a true relapse rather than the appearance of a temporarily suppressed erythrocytic phase.
Pamaquine has a curative action in vivax malaria which is clearly apparent when the drug is given at high dosage, in combination with quinine and for a period of 14 days. Pamaquine administered alone has a curative action but this is not clearly defined by the experimental data presented here (cf. group V, Table V ). The data which bear on the curative action of pamaquine also Interval from treatment with combined quinine and pamaquine to relapse in individuals with sporozoiteinduced vivax malaria (Chesson strain) Each attack was treated with 2 grams of quinine (base) daily for two days, followed by concurrent administration of 2 grams of quinine and 60 mg. of pamaquine daily for 14 days. (sporozoite dosage Tables V, VI, VII) . Presumably, this is an important factor in determining the history of the disease when acquired naturally.
The data define the curative dosage of pamaquine for Chesson malaria in terms of the amount required to cure primary attacks resulting from heavy sporozoite dosage. This would appear to be in the range of 60-90 mg. of pamaquine base when administered in conjunction with 2.0 grams of quinine for 14 days.
It seems likely that curative effects observed at lower dosages (8, 12) are attributable to greater strain susceptibility, to the administration of drug at a later stage of the disease, or to a lesser density of the underlying tissue infection. The latter two circumstances may, in fact, be related. That is, a lesser density of the underlying tissue phase of the disease may result from either a smaller sporozoite inoculum or a diminution with time of an initially high density of tissue parasites.
Contrary to the situation encountered in the study of a number of suppressive antimalarials (13, 14, 4. There is no correlation between plasma pamaquine concentration and antimalarial effect whether suppressive or curative.
